Schizophrenia :: ABILIFY, Aripiprazole for Adults With Agitation Associated With Schizophrenia or Bipolar Mania

Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY? (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours).

The U.S. Food and Drug Administration (FDA) approved ABILIFY Injection on Septem_ber_20, 2006.

The urgent nature of acute agitation requires immediate assessment and intervention. ABILIFY Injection provides healthcare professionals with the first ready-to-use single-dose vial (9.75 mg/1.3 mL) of an atypical antipsychotic to calm the agitated patient.

“Acute agitation can be very serious, distressing and potentially dangerous for patients, healthcare professionals and caregivers,” said Michael H. Allen, MD, Director, Emergency Psychiatry, Associate Professor, University of Colorado at Denver and Health Sciences Center’s School of Medicine. “ABILIFY Injection controls agitation independent of sedation.”


Leave a Comment